Actively Recruiting
Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease
Led by University of Pittsburgh · Updated on 2025-12-19
116
Participants Needed
1
Research Sites
229 weeks
Total Duration
On this page
Sponsors
U
University of Pittsburgh
Lead Sponsor
N
National Institute on Aging (NIA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Dementia caused by Alzheimer's disease affects approximately 5.6 million adults over age 65, with costs expected to rise from $307 billion to $1.5 trillion over the next 30 years. Behavioral interventions have shown promise for mitigating neurodegeneration and cognitive impairments. Sleep is a modifiable health behavior that is critical for cognition and deteriorates with advancing age and Alzheimer's disease. Thus, it is a priority to examine whether improving sleep modifies Alzheimer's disease pathophysiology and cognitive function. Extant research suggests that deeper, more consolidated sleep is positively associated with memory and executive functions and networks that underlie these processes. Preliminary studies confirm that time-in-bed restriction interventions increase sleep efficiency and non-rapid eye movement slow-wave activity (SWA) and suggest that increases in SWA are associated with improved cognitive function. SWA reflects synaptic downscaling predominantly among prefrontal connections. Downscaling of prefrontal connections with the hippocampus during sleep may help to preserve the long-range connections that support memory and cognitive function. In pre-clinical Alzheimer's disease, hyperactivation of the hippocampus is thought to be excitotoxic and is shown to leave neurons vulnerable to further amyloid deposition. Synaptic downscaling through SWA may mitigate the progression of Alzheimer's disease through these pathways. The proposed study will behaviorally increase sleep depth (SWA) through four weeks of time-in-bed restriction in older adults characterized on amyloid deposition and multiple factors associated with Alzheimer's disease risk. This study will examine whether behaviorally enhanced SWA reduces hippocampal hyperactivation, leading to improved task-related prefrontal-hippocampal connectivity, plasma amyloid levels, and cognitive function. This research addresses whether a simple, feasible, and scalable behavioral sleep intervention improves functional neuroimaging indices of excitotoxicity, Alzheimer's pathophysiology, and cognitive performance.
CONDITIONS
Official Title
Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 65 and 85 years
- Self-reported sleep efficiency below 90% and wake time after sleep onset over 20 minutes based on diaries and actigraphy
- Normal or corrected-to-normal vision and hearing
You will not qualify if you...
- Night shift or work regularly between 12 am and 6 am
- Chronic conditions that significantly affect sleep
- Severe psychiatric disorders or substance abuse within the past 6 months or lifetime history of psychotic or bipolar I disorders
- Current use of medications affecting sleep, including antidepressants, antipsychotics, anticonvulsants, steroids, or sedating drugs at bedtime
- Consuming more than 14 alcoholic drinks per week or more than 6 drinks in a single sitting
- Consuming more than 3 caffeine drinks per day
- Prior diagnosis of central nervous system diseases such as multiple sclerosis, stroke, Parkinson's disease, Alzheimer's disease, seizure disorder, delirium, dementia, loss of consciousness over 24 hours, or traumatic brain injury
- Sleep efficiency over 90% and wake time after sleep onset less than 20 minutes
- Apnea-hypopnea index greater than 15
- Presence of metal implants or exposure preventing MRI scans
- Claustrophobia
- Severe obesity with BMI over 40
- Near-miss or prior automobile accident due to sleepiness in the past 12 months
- Employment as a commercial driver during the study
- Telephone Interview for Cognitive Status score below 23
- Epworth Sleepiness Scale score greater than 10
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UPMC Western Psychiatric Hospital
Pittsburgh, Pennsylvania, United States, 15213
Actively Recruiting
Research Team
K
Kristine Wilckens, PhD.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here